Abstract 4368956: 2-Deoxyuridine Associates with Recurrent Coronary Events

Background: Altered metabolic pathways underlie atherosclerosis and acute coronary events. Objectives: We investigated the association between circulating metabolites and recurrent coronary events among patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) and used preclinical models of atherosclerosis to gain mechanistic insights into significant metabolite associations. Methods: A total of 61 plasma metabolites were quantified in medically managed patients 30 days following the index ACS (N=490) to investigate their association with secondary myocardial infarction (MI). Patients with ACS were eligible if they were selected for a final treatment strategy of medical management without revascularisation within 10 days after the index NSTE-ACS event. To complement this analysis, we assessed the effect of one metabolite significantly associated with subsequent spontaneous MI using LDL receptor-deficient ( Ldlr -/- ) mice (n=5/group) subjected to carotid wire injury to simulate endothelial disruption. Results: MI occurred in 35 patients (7.14%) during follow-up (median time to MI: 6 months, range 1-31 months). Higher 30-day levels of 2-deoxyuridine (2dU), a pyrimidine substrate of DNA synthesis, were associated with a high risk of subsequent MI (adjusted hazard ratio: 17.0; 95% confidence interval 3.0 to 97; p=0.002), which was confirmed in a replication cohort. Daily administration of 250 mg/kg of 2dU increased neointimal plaques in carotid wire-injured mice (p=0.04), which was reversed by the co-administration of AR-C118925 (7 mg/kg), a specific P2Y 2 receptor (P2Y 2 R) antagonist (p=0.003) (Fig 1A). Additionally, lesional VSMCs (α-SMA + ) were significantly increased upon administration of 2dU. This was also reversed with the P2Y 2 R blockade via AR-C118925 co-administration (Fig 1B). Exposing human coronary artery smooth muscle cells (HCASMC) to 2dU (10µM) increased proliferation, migration, and loss of contractility, effects which were inhibited by AR-C118925 (Fig 1C). Transcriptomic analyses confirmed differential modulation of gene expression by 2dU in HCASMCs versus human coronary artery endothelial cells (HCAECs), with modulation of genes in the MAPK, PI3K-AKT, and TNF signaling pathways in HCASMCs but not HCAECs. Conclusions: Elevated circulating 2-deoxyuridine levels are associated with an increased risk of MI after NSTE-ACS by increasing neointima formation possibly via P2Y 2 R-dependent VSMCs alterations following endothelial injury.